Biopharmaceutical company Clovis Oncology, backed by Pfizer, sells the shares following its initial public offering in November last year.
US-based biopharmaceutical company Clovis Oncology raises $75m through follow-on offering
The deal follows Clovis’ initial public offering (IPO) on November 15, offering 10 million shares at $13.00 per share, raising a total of $130m.
Clovis is focused on acquiring, developing and commercialising anti-cancer agents in the US, Europe and additional international markets.
Founded in 2009 a year after its management team sold Pharmion for $2.9bn to peer Celgene, Clovis closed a $146m series A in May of that year…
